Showcasing Natural Killer (NK) Cell Derived EVs as a New Treatment for Patients with Relapsed/Refractory Cancers
Time: 4:00 pm
day: Conference Day Two
Details:
- Demonstrating NK EVs’ strong and broad anti-tumor activity without harming healthy cells
- Developing a new off-the-shelf biological product widely available to treat cancer patients who fail current treatments
- Identifying a quantitative biomarker of NK EV activity
NEW COMPANY!
